news
ALLY Trial demonstrates high cure rates for investigational daclatasvir and sofosbuvir combination among genotype 3 hepatitis C patients
Bristol-Myers Squibb Company announced late-breaking data from the landmark ALLY…
10 November 2014 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company announced late-breaking data from the landmark ALLY Trial investigating a ribavirin-free 12-week regimen of daclatasvir (DCV) in combination with sofosbuvir (SOF) in genotype 3 hepatitis C (HCV) patients, a patient population that has emerged as one of the most difficult to treat...
